Drugs /

glyco-engineered anti-cd20 monoclonal antibody cho h01

Back to Drugs List

Overview

NCI Definition [1]:
A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.

Clinical Trials

View Clinical Trials for glyco-engineered anti-cd20 monoclonal antibody cho h01

Glyco-engineered anti-cd20 monoclonal antibody cho h01 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating glyco-engineered anti-cd20 monoclonal antibody cho h01, 1 is phase 1 (1 open).

MS4A1 Expression is the most frequent biomarker inclusion criterion for glyco-engineered anti-cd20 monoclonal antibody cho h01 clinical trials.

Follicular lymphoma is the most common disease being investigated in glyco-engineered anti-cd20 monoclonal antibody cho h01 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Glyco-Engineered Anti-Cd20 Monoclonal Antibody Cho H01
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating glyco-engineered anti-cd20 monoclonal antibody cho h01 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cho-h01, cho h01
Drug Target(s) [2]:
MS4A1
NCIT ID [1]:
C151952

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.